Shield Therapeutics (STU:1JS) Change In Inventory: €-2.94 Mil (TTM As of Dec. 2025)


What is Shield Therapeutics Change In Inventory?

Shield Therapeutics STU:1JS +1.47% Change In Inventory is €-2.94 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

Shield Therapeutics's change in inventory for the quarter that ended in Dec. 2025 was €-2.32 Mil. It means Shield Therapeutics's inventory increased by €2.32 Mil from Jun. 2025 to Dec. 2025 .

Shield Therapeutics's change in inventory for the fiscal year that ended in Dec. 2025 was €-2.93 Mil. It means Shield Therapeutics's inventory increased by €2.93 Mil from Dec. 2024 to Dec. 2025 .

Shield Therapeutics's Total Inventories for the quarter that ended in Dec. 2025 was €7.87 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Shield Therapeutics's Days Inventory for the quarter that ended in Dec. 2025 was 92.77.

Inventory Turnover measures how fast the company turns over its inventory within a year. Shield Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2025 was 1.97.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Shield Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.28.

Shield Therapeutics  (STU:1JS) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Shield Therapeutics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=6.86/13.495*365 / 2
=92.77

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Shield Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2025 is calculated as

Inventory Turnover=Cost of Goods Sold / Average Total Inventories
=13.495 / 6.86
=1.97

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Shield Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as

Inventory-to-Revenue=Average Total Inventories / Revenue
=6.86 / 24.129
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shield Therapeutics Change In Inventory Related Terms

Shield Therapeutics Change In Inventory Historical Data

* Premium members only.

The historical data trend for Shield Therapeutics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shield Therapeutics Change In Inventory Chart

Shield Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.31 0.20 -1.33 -2.35 -2.93

Shield Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.47 -0.77 -1.55 -0.62 -2.32

Shield Therapeutics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-2.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Inventory →
What does a Change In Inventory of €-2.94 Mil mean?
Shield Therapeutics (STU:1JS) has a Change In Inventory of €-2.94 Mil as of Dec. 2025. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Shield Therapeutics and its competitors.
Is Shield Therapeutics' Change In Inventory too high?
Shield Therapeutics' current Change In Inventory is €-2.94 Mil.
How does Shield Therapeutics' Change In Inventory compare to ZTS and UTHR?
Shield Therapeutics' Change In Inventory of €-2.94 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Drug Manufacturers company?
A good Change In Inventory depends on the Drug Manufacturers industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Shield Therapeutics and its competitors. Shield Therapeutics's current Change In Inventory is €-2.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (STU:1JS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.10, compared to a current price of €0.07 — trading 31% below its estimated fair value. The current Change In Inventory is €-2.94 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Shield Therapeutics (STU:1JS), the current Change In Inventory is €-2.94 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shield Therapeutics Business Description

Other Exchanges SHIEF:USASTX:UK1JS:Germany
Address Gateshead Quays, Northern Design Centre, Baltic Business Quarter, Newcastle, GBR, NE8 3DF
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.